NEW YORK, NY / ACCESSWIRE / November 18, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=11029&wire=1
MESO Shareholders Click Here: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=11029&wire=1
LOOP Shareholders Click Here: https://www.zlk.com/pslra-1/loop-industries-inc-loss-submission-form?prid=11029&wire=1
* ADDITIONAL INFORMATION BELOW *
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BMRN Lawsuit on behalf of: investors who purchased February 28, 2020 - August 18, 2020
Lead Plaintiff Deadline: November 24, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form?prid=11029&wire=1
According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Mesoblast Limited (NASDAQ:MESO)
MESO Lawsuit on behalf of: investors who purchased April 16, 2019 - October 1, 2020
Lead Plaintiff Deadline: December 7, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/mesoblast-limited-loss-submission-form?prid=11029&wire=1
According to the filed complaint, during the class period, Mesoblast Limited made materially false and/or misleading statements and/or failed to disclose that: (1) comparative analyses between Mesoblast's Phase 3 trial and three historical studies did not support the effectiveness of the Company's lead product candidate, remestemcel-L, for steroid refractory acute graft versus host disease due to design differences between the four studies; (2) as a result, the US Food and Drug Administration was reasonably likely to require further clinical studies; (3) as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Loop Industries, Inc. (NASDAQ:LOOP)
LOOP Lawsuit on behalf of: investors who purchased September 24, 2018 - October 12, 2020
Lead Plaintiff Deadline: December 14, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/loop-industries-inc-loss-submission-form?prid=11029&wire=1
According to the filed complaint, during the class period, Loop Industries, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Loop scientists were encouraged to misrepresent the results of Loop's purportedly proprietary process; (2) Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) as a result, the Company was unlikely to realize the purported benefits of Loop's announced partnerships with Indorama Ventures Public Company Limited and thyssenkrupp Industrial Solutions; and (4) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
https://www.zlk.com
SOURCE: Levi & Korsinsky, LLP